中国医药科学Issue(5)：209-211,3.
培美曲塞与吉西他滨联合卡铂一线治疗晚期非小细胞肺癌的安全性和有效性临床研究
Safety and efficacy in clinical studies on pemetrexed and gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer
吴雪婷 1潘学兵 2丁少波 1万惠青1
作者信息
- 1. 广东省东莞市人民医院药剂科，广东东莞523059
- 2. 广东省东莞市人民医院肿瘤内科，广东东莞523059
- 折叠
摘要
Abstract
Objective To compare the clinical efficacy and adverse reactions of the pemetrexed and gemcitabine compared with carboplatin in first-line treatment of advanced non-small cell lung cancer,and explore the feasibility of the program. Methods 37 cases of histologically confirmed advanced non-small cell lung cancer patients were selected from the new hospital(from May 2011 to November 2012),they were randomly divided into two groups according to the treatment plan: group A included 19 cases,they used pemetrexed and carboplatin; group B included 18 cases, they used gemcitabine and carboplatin. The efficacy and adverse reactions of chemotherapy were evaluated after three weeks. Results (1)There were no significant difference in ORR and DCR between group A and group B(P > 0.05).(2)PFS of group A was higher than group B, the difference was significant(P < 0.05).There were no significant difference in 1-year overall survival between group A and group B(P > 0.05).(3)The side effects rate of group A was lower than group B,the difference was significant(P < 0.05). Conclusion The efficacy of pemetrexed and carboplatin in first-line treatment of advanced non-small cell lung cancer and efficacy of gemcitabine and carboplatin are similar,and well tolerated,can significantly improve patient's compliance and can be extended to the clinic.关键词
培美曲塞/吉西他滨/卡铂/非小细胞肺癌Key words
Pemetrexed/Gemcitabine/Carboplatin/Non-small cell lung cancer分类
医药卫生引用本文复制引用
吴雪婷,潘学兵,丁少波,万惠青..培美曲塞与吉西他滨联合卡铂一线治疗晚期非小细胞肺癌的安全性和有效性临床研究[J].中国医药科学,2014,(5):209-211,3.
